Novartis on course to set new highs
20/02/24 -"Considering the strong operational performance and a meaningful progress for the late-stage pipeline in recent years, we have revised upwards our NAV estimates by c.10%."
Pages
72
Language
English
Published on
20/02/24
You may also be interested by these reports :
14/10/26
Lonza presented its mid-term outlook at its CMD today in Vacaville (US). The group unveiled ambitious targets, aiming for 10–13% average CER sales ...
14/10/26
Since we last teased Genmab’s (ADD; Denmark) story – a company that specialises in developing antibodies for cancer treatment – in February 2025, the ...
07/10/26
Our estimates are already at the higher end, with our target price significantly benefitting from increased NAV and DCF estimates, as well as a ...
30/09/26
Lundbeck, as per Bloomberg, is pursuing endocrine- and neurology-focused Xeris Biopharma, whose market cap is c.28% of that of Lundbeck. Considering ...